Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

NCT04795427 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Chronic Myelogenous

Interventions

DRUG: asciminib
OTHER: best available treatment

Sponsor

Novartis Pharmaceuticals